Medicrea wins FDA approval for TULIP GENESIS solution

5 August 2019 (Last Updated August 5th, 2019 11:18)

The Medicrea Group has secured approval from the US FDA for its top-loading screw solution TULIP GENESIS, completing its UNiD Adaptive Spine Intelligence (ASI) platform technology.

The Medicrea Group has secured approval from the US FDA for its top-loading screw solution TULIP GENESIS, completing its UNiD Adaptive Spine Intelligence (ASI) platform technology.

TULIP GENESIS has been designed to integrate with the UNiD ASI platform and can be used with the UNiD ROD.

Along with the latest product, Medicrea’s implant database integrated within the UNiD HUB now includes IB3D, UNiD ROD and PASS LP.

Medicrea president and CEO Denys Sournac said: “To date, we have performed more than 4,000 cases using the UNiD ASI technology, with a strong and continuous adoption rate in the US of +47% since the beginning of the year.

“With the adoption of the UNiD ASI technology accelerating, Medicrea created a unique opportunity for a pull-through effect by offering surgeons a complete solution of implants.”

The company’s UNiD ASI technology comprises services and products designed to help surgeons improve their patient’s outcomes.

The platform leverages artificial intelligence (AI) and the latest clinical research and enables them to plan cases preoperatively.

With the AI embedded within the platform, a surgeon will be able to visualise the compensatory mechanisms above and below the instrumented spine that are expected to occur based on their surgical plan.

The technology offers solutions designed for complex deformity as well as degenerative applications.

The UNiD LAB team of biomedical engineers of the company can generate documented surgical plans, using outcome-centred predictive modelling algorithms to optimise surgical strategy.

With the help of these plans, the operating room staff can anticipate the need for each implant.